Science & Tech · United States of America, Germany
Deisseroth, Hegemann and Nagel win medicine Nobel for optogenetics
The 2026 prize recognises discoveries that enabled light-based control of selected nerve cells. The method is widely used in laboratories and has been tested experimentally in people with an inherited form of blindness, but no established therapy is documented.
Listen to the story
Short version
The 2026 medicine Nobel honours the development of optogenetics, which controls selected nerve cells with light; new reporting shows laureate Karl Deisseroth's disorienting morning after the win.
- Deisseroth, Hegemann and Nagel share the medicine Nobel.
- Deisseroth called the news "very disorienting" and got no real sleep.
- He made his kids' school lunches after taking celebratory calls.
- Experimental work restored some light sensitivity in people with retinitis pigmentosa.
- The prize totals 12 million Swedish kronor.
Infographic
What's new
- Karl Deisseroth said learning of the award was "very disorienting" and that he got no real sleep before taking a string of celebratory calls, The Associated Press reported.
- Deisseroth, a Stanford physician-scientist and psychiatrist who treats patients with autism and depression, then made his children's school lunches before they woke for school.
- Michelle Monje-Deisseroth, his wife, who works as an HHMI investigator and treats children with cancer at Stanford, pointed out that several other Nobel winners also live in their university housing community.
- The three laureates share a prize of 12 million Swedish kronor.
On Oct. 5, the Karolinska Institutet’s Nobel Assembly in Stockholm jointly awarded the 2026 prize in physiology or medicine to Georg Nagel, Peter Hegemann and Karl Deisseroth. The award recognises discoveries involving light-gated ion channels and optogenetics, a method researchers use to control selected nerve cells with light and investigate how brain circuits shape memories, feelings and behaviour.1246
Infographic
A light-controlled neural switch
Optogenetics combines light with genetic modification to activate or silence selected nerve cells. Using this approach, scientists can activate or suppress specific brain pathways, helping them chart neural activity and assess what distinct neuron classes do. The Nobel committee said the technology is used in laboratories around the world.123
The work began with light-sensitive proteins in the single-celled alga Chlamydomonas. Hegemann and colleagues showed that light caused a rapid flow of ions, and Hegemann and Nagel characterised two light-sensitive genes and the proteins now known as channelrhodopsins. These proteins open ion channels when illuminated, providing the molecular basis for optogenetics.356
Deisseroth and colleagues showed that channelrhodopsins function in neurons and that the resulting ion flows can become nerve impulses. His team demonstrated light-triggered signalling in rat nerve cells, and subsequent work enabled researchers to control neurons in living mice. Compact light sources and flexible fibre optics later made experiments possible in freely moving animals.15614
The resulting technique gave scientists precise control over selected populations of neurons. Researchers have used light-controlled circuits in animals to evoke memories, produce feelings and prompt behaviours, while studying the neural pathways involved. Per Svenningsson, who leads the Nobel Committee for Physiology or Medicine, said optogenetics enables forms of brain mapping that had once seemed unimaginable.349
From laboratory tool to medical research
The Nobel Assembly said optogenetics had fundamentally changed understanding of the brain. The method has helped researchers identify circuits associated with particular memories, emotions and behaviours, including circuits relevant to neurological and psychiatric disorders. It has also allowed scientists to examine the types of neurons involved in those conditions.13
Potential medical applications remain under investigation. Researchers are exploring vision restoration and possible uses involving depression, addiction, dementia, Parkinson’s disease and epilepsy. In an interview with WBUR, Deisseroth said optogenetics had been tested in people with retinitis pigmentosa, restoring light sensitivity and allowing some participants to see things they previously could not. This remains experimental, and the dossier does not establish an effective clinical therapy or widespread medical use.11113
Deisseroth works at Stanford University in California; Hegemann is at Berlin's Humboldt University; and Nagel is affiliated with Germany's University of Würzburg. Thomas Perlmann, the medicine Nobel committee's secretary, said he spoke with each of the three winners by phone on the announcement day.2
The prize totals 12 million Swedish kronor, equivalent to just over €1 million or about $1.2 million. It opened the week of Nobel announcements, with the physics, chemistry, literature and peace prizes to follow and the Nobel Memorial Prize in Economic Sciences scheduled for Oct. 12. The medicine laureates are due to receive diplomas and gold medals from Sweden’s king at a ceremony in Stockholm on Dec. 10.1212
A Nobel morning in Stanford
Karl Deisseroth learned of the prize at his home near Stanford University, where the Nobel Assembly reached him by phone. He called the experience "very disorienting" and said he got no real sleep afterward, spending the morning taking congratulatory calls and media interviews.812
After roughly an hour, Deisseroth paused to make school lunches before his children woke up, with The Associated Press present at the family home. His wife Michelle Monje-Deisseroth, a Stanford pediatric neuro-oncologist and HHMI investigator, remarked that their faculty housing area already includes a number of other Nobel Prize winners. Deisseroth described himself as a physician-scientist and psychiatrist who treats patients with autism and depression, in addition to his basic-science work on the brain.8
Why it matters
Two laureates work at German universities, placing European institutions at the centre of a technology widely used to study brain circuits. Deisseroth said optogenetics had restored some light sensitivity in experimental work involving people with retinitis pigmentosa, but the dossier does not establish an effective clinical therapy or broad medical use.1211
Videos
Related stories
Version history
- version 4 · Added new reporting on Karl Deisseroth's personal reaction and morning routine after learning he had won the Nobel Prize.
- version 3 · The update adds reported human testing in retinitis pigmentosa and clarifies how channelrhodopsins convert light-driven ion flows into neural signals.
- version 2 · The update fixes the lede’s date, adds details of the Dec. 10 presentation and clarifies the technical and safety barriers facing clinical use.
- version 1 ·
